Business Insider

Dompé receives FDA approval of Oxervate™ eye drops (cenegermin-bkbj ophthalmic solution), first-in-class recombinant human nerve growth factor with potential to completely ...

MILAN and SAN BRUNO, Calif., Aug. 22, 2018 /PRNewswire/ -- Dompé today announced that the U.S. Food and Drug Administration (FDA) has approved Oxervate TM (cenegermin-bkbj ophthalmic solution), a ...
Medical News Today

A guide to Oxervate for neurotrophic keratitis

Oxervate is a prescription eye drop approved for the treatment of neurotrophic keratitis. It is suitable for adults and children ages two years and older. Oxervate is a brand-name prescription drug ...
Healio

Neurotrophic keratitis landscape improving, yet many hurdles remain

Please provide your email address to receive an email when new articles are posted on . Oxervate, approved by the FDA in 2018, treats the underlying cause of neurotrophic keratitis. Other treatment ...
Business Insider

Dompé Announces First Patient Enrollment in Phase 2b Clinical Trial Investigating Novel Mechanism of Action in Moderate to Severe Dry Eye Disease

MILAN and SAN MATEO, Calif., June 25, 2019 /PRNewswire/ -- Dompé Farmaceutici S.p.A and Dompé U.S. Inc., (collectively Dompé) announced today that the first patient has been enrolled in Study NGF0118, ...
Finanznachrichten

OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer

Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate, a blockbuster orphan therapy in corneal disease Dr. Mantelli ...